Efficacy of appropriate antimicrobial therapy on the survival of patients with carbapenem nonsusceptible klebsiella pneumoniae infection

Medicine (United States)

Volumn 94, Issue 33, 2015, Pages e1405-

  Lin, Yi Tsung ^a,b   Chuang, Chien ^a   Su, Chin Fang ^a   Chan, Yu Jiun ^a,b   Wang, Lih Shinn ^c   Huang, Ching Tai ^d   Chuang, Yin Ching ^e   Siu, L Kristopher ^f   Fung, Chang Phone ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; DORIPENEM; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

AGE; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; CARBAPENEM NONSUSCEPTIBLE KLEBSIELLA PNEUMONIAE INFECTION; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; INAPPROPRIATE PRESCRIBING; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIC50; MIC90; MIXED INFECTION; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL; TAIWAN; CLINICAL TRIAL; DRUG EFFECTS; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MEDICATION THERAPY MANAGEMENT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX;

AGED; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; IMIPENEM; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MEDICATION THERAPY MANAGEMENT; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; TAIWAN; THIENAMYCINS;

EID: 84943184387     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001405     Document Type: Article

References (29)

1. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998; 11: 589-603
2. Meatherall BL, Gregson D, Ross T, et al. Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med. 2009; 122: 866-873
3. Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012; 25: 682-707
4. Petrosillo N, Giannella M, Lewis R, et al. Treatment of carbapenemresistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013; 11: 159-177
5. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012; 18: 263-272
6. Patel G, Bonomo RA. Stormy waters ahead": global emergence of carbapenemases. Front Microbiol. 2013; 4: 48
7. Chiu SK, Wu TL, Chuang YC, et al. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PloS one. 2013; 8: e69428
8. van Duin D, Kaye KS, Neuner EA, et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013; 75: 115-120
9. Vardakas KZ, Matthaiou DK, Falagas ME, et al. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect. 2015; 70: 592-599 (in press).
10. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012; 56: 2108-2113
11. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009; 53: 1868-1873
12. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 55: 943-950
13. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011; 17: 1798-1803
14. Clinical, Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: Twenty-Second Informational Supplement. M100-S22. Wayne PA: CLSI; 2012
15. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0 ed. Available: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/EUCAST-Breakpoint-table-v-3.0.pdf. 2013
16. Department of Health and Human Services, Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test systems (AST): guidance for industry. Washington, DC. USA. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM169359.pdf. 2009
17. van Duin D, Perez F, Rudin SD, et al. Surveillance of carbapenemresistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother. 2014; 58: 4035-4041
18. Wu HS, Wang FD, Tseng CP, et al. Characteristics of healthcareassociated and community-Acquired Klebsiella pneumoniae bacteremia in Taiwan. J Infect. 2012; 64: 162-168
19. Lin YT, Wang FD, Chan YJ, et al. Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniae bacteremia in Taiwan. BMC Infect Dis. 2014; 14: 1
20. Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009; 53: 2756-2761
21. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome?. Clin Infect Dis. 2007; 44: 87-93
22. Lee YT, Kuo SC, Yang SP, et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis. 2012; 55: 209-215
23. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-Producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014; 58: 2322-2328
24. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015; 70: 2133-2143
25. Bass SN, Bauer SR, Neuner EA, et al. Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia. Antimicrob Agents Chemother. 2015; 59: 3748-3753
26. Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014; 20: 862-872
27. Daikos GL, Markogiannakis A, Souli M, et al. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther. 2012; 10: 1393-1404
28. Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014; 69: 2305-2309
29. De Oliveira MS, De Assis DB, Freire MP, et al. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microbiol Infect. 2015; 21: 179e1-1797e.